Skip to main content
Sonoma Pharmaceuticals, Inc. logo

Sonoma Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · SNOA ISIN · US83558L2043 US Manufacturing
Open in API
Filings indexed 951 across all filing types
Latest filing 2011-02-18 Regulatory Filings
Country US United States of America
Listing US SNOA

About Sonoma Pharmaceuticals, Inc.

https://sonomapharma.com/

Sonoma Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops and commercializes products based on its patented Microcyn® Technology, a stabilized hypochlorous acid (HOCl) platform. With over 20 years of experience, the company produces a range of prescription and over-the-counter solutions for advanced wound care, dermatology, animal health, and eye care. Its products are designed to manage various conditions by promoting healing and reducing the risk of infection. The portfolio serves healthcare professionals in settings like hospitals and nursing homes, as well as consumers for at-home use.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2011
Regulatory Filings Classification · 95% confidence The document is a letter from the company's securities counsel and CEO responding to comments from the SEC staff regarding a Registration Statement on Form S-3 and the company's Form 10-K for the fiscal year ended March 31, 2010. It references the Form 10-K and the Registration Statement but does not contain the actual Form 10-K report or financial data. The document is primarily a regulatory correspondence acknowledging SEC comments and the company's responsibilities. The length is under 5,000 characters and it serves as a response to regulatory comments rather than the report itself. Therefore, it fits best under Regulatory Filings (RNS) as it is a regulatory correspondence and not the actual annual report or registration statement filing.
2011-02-18 English
Capital/Financing Update 2011
Capital/Financing Update Classification · 95% confidence The document is a Form S-3/A, which is an amendment to a registration statement filed under the Securities Act of 1933. It is used by companies to register securities for sale to the public, often as part of a shelf registration allowing multiple offerings over time. The text includes details about the securities to be registered (common stock, preferred stock, warrants, units), the maximum aggregate offering price, and the terms of the offering. It also contains a prospectus with company information, risk factors, and legal disclaimers. This type of filing is related to capital raising and financing activities rather than financial reporting, management changes, or other categories. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it is not merely an announcement of a report but the actual registration statement amendment filing. Confidence is high due to the clear identification of the form and its purpose.
2011-02-18 English
Regulatory Filings 2011
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated February 14, 2011, by Oculus Innovative Sciences, Inc. It reports entry into material definitive agreements including sales, distribution, co-promotion, and product option agreements. The content focuses on announcements of new contracts and agreements rather than financial results or detailed financial statements. There is no indication of quarterly or annual financial data, audit information, or management discussion of financial results. The document is a current report on material events, which fits the category of a Regulatory Filing (RNS) as it does not fit into more specific categories like earnings release, annual report, or capital update. The length of the document (6708 characters) and the detailed description of agreements support this classification rather than a brief announcement or a full report.
2011-02-18 English
QUARTERLY REPORT
Interim / Quarterly Report Q3 2011
2011-02-04 English
Earnings Release 2011
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated February 3, 2011, reporting the issuance of a press release announcing financial results for the fiscal quarter ended December 31, 2010. The text states that the full press release is furnished as an exhibit, indicating this document is a current report announcing the earnings release rather than the earnings release itself. The document length is 4186 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this filing is best classified as an Earnings Release (ER) announcement, as it primarily serves to announce quarterly financial results.
2011-02-03 English
Regulatory Filings 2011
Regulatory Filings Classification · 95% confidence The document is a letter from the company's securities counsel responding to comments from the SEC staff regarding the company's previously filed Form 10-K for the fiscal year ended March 31, 2010. The letter discusses detailed regulatory compliance issues, related party transactions, and references specific SEC filings such as the 10-K and 10-Q. It is not the 10-K report itself but a correspondence related to regulatory review and comment responses. The document length is 9652 characters, which is substantial but the content is clearly a comment response letter rather than a financial report or audit report. This type of document fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory correspondence and compliance documents that do not fit other specific categories.
2011-01-21 English

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.